- Home
- NEWT vs ABEO Comparison
NEWT vs ABEO Comparison
Compare NEWT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | ABEO |
|---|---|---|
| Founded | 1998 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | NEWT | ABEO |
|---|---|---|
| Price | $11.32 | $5.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.25 | ★ $18.20 |
| AVG Volume (30 Days) | 200.2K | ★ 2.4M |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | ★ 32.88 | N/A |
| EPS | ★ 2.23 | 1.29 |
| Revenue | ★ $380,364,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.56 | $1,590.36 |
| P/E Ratio | $5.04 | ★ $4.03 |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $9.12 | $3.93 |
| 52 Week High | $14.50 | $7.54 |
Technical Indicators
Market Signals| Indicator | NEWT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 57.89 |
| Support Level | $9.59 | $4.53 |
| Resistance Level | $11.40 | $4.92 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | 0.17 | 0.08 |
| Stochastic Oscillator | 92.82 | 85.71 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.